Role of dopamine transporter imaging in routine clinical practice
Identifieur interne : 001713 ( Main/Exploration ); précédent : 001712; suivant : 001714Role of dopamine transporter imaging in routine clinical practice
Auteurs : Vicky Marshall [Royaume-Uni] ; Donald Grosset [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-12.
English descriptors
- KwdEn :
Abstract
Functional imaging of the dopamine transporter (DAT) defines integrity of the dopaminergic system and has its main clinical application in patients with mild, incomplete, or uncertain parkinsonism. Imaging with specific single positron emission computerised tomography ligands for DAT (FP‐CIT, β‐CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration. Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs. DAT imaging is abnormal in idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy and does not distinguish between these disorders. Dopamine loss is seen even in the earliest clinical presentations of true parkinsonism; a normal scan suggests an alternative diagnosis such as essential tremor, vascular parkinsonism (unless there is focal basal ganglia infarction), drug‐induced parkinsonism, or psychogenic parkinsonism. Congruence between working clinical diagnosis and DAT imaging increases over time in favour of baseline DAT imaging results. Additional applications are characterising dementia with parkinsonian features (abnormal results in dementia with Lewy bodies, normal in Alzheimer's disease); and differentiating juvenile‐onset Parkinson's disease (abnormal DAT) from dopa‐responsive dystonia (normal DAT). © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10592
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of dopamine transporter imaging in routine clinical practice</title><author><name sortKey="Marshall, Vicky" sort="Marshall, Vicky" uniqKey="Marshall V" first="Vicky" last="Marshall">Vicky Marshall</name></author><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:516974B861F0EB8DB9A7DA5A786468D824F38F88</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10592</idno><idno type="url">https://api.istex.fr/document/516974B861F0EB8DB9A7DA5A786468D824F38F88/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001D36</idno><idno type="wicri:Area/Main/Curation">001A56</idno><idno type="wicri:Area/Main/Exploration">001713</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Role of dopamine transporter imaging in routine clinical practice</title><author><name sortKey="Marshall, Vicky" sort="Marshall, Vicky" uniqKey="Marshall V" first="Vicky" last="Marshall">Vicky Marshall</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurological Sciences, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurological Sciences, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-12">2003-12</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1415">1415</biblScope><biblScope unit="page" to="1423">1423</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">516974B861F0EB8DB9A7DA5A786468D824F38F88</idno><idno type="DOI">10.1002/mds.10592</idno><idno type="ArticleID">MDS10592</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>diagnosis</term><term>dopamine transporter</term><term>emission computed</term><term>essential tremor</term><term>tomography</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Functional imaging of the dopamine transporter (DAT) defines integrity of the dopaminergic system and has its main clinical application in patients with mild, incomplete, or uncertain parkinsonism. Imaging with specific single positron emission computerised tomography ligands for DAT (FP‐CIT, β‐CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration. Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs. DAT imaging is abnormal in idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy and does not distinguish between these disorders. Dopamine loss is seen even in the earliest clinical presentations of true parkinsonism; a normal scan suggests an alternative diagnosis such as essential tremor, vascular parkinsonism (unless there is focal basal ganglia infarction), drug‐induced parkinsonism, or psychogenic parkinsonism. Congruence between working clinical diagnosis and DAT imaging increases over time in favour of baseline DAT imaging results. Additional applications are characterising dementia with parkinsonian features (abnormal results in dementia with Lewy bodies, normal in Alzheimer's disease); and differentiating juvenile‐onset Parkinson's disease (abnormal DAT) from dopa‐responsive dystonia (normal DAT). © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Marshall, Vicky" sort="Marshall, Vicky" uniqKey="Marshall V" first="Vicky" last="Marshall">Vicky Marshall</name></noRegion><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001713 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001713 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:516974B861F0EB8DB9A7DA5A786468D824F38F88
|texte= Role of dopamine transporter imaging in routine clinical practice
}}
| This area was generated with Dilib version V0.6.23. |  |